PEPTOKING
DA

Forsøg at følge

Igangværende og nyligt afsluttede kliniske forsøg med peptiderne i kataloget. Fase, status, antal deltagere og datoer kommer fra ClinicalTrials.gov og ændrer sig, når sponsorerne opdaterer registret.

Primær afslutning er det tidspunkt, hvor den sidste deltager måles på det primære effektmål; resultaterne følger som regel måneder senere. Registerdata tjekket 2. okt. 2026.

Resultater ventes

  1. Fase 3Aktivt, rekrutterer ikke

    STEP Young(åbner kilden i en ny fane)

    A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

    Primær afslutning 15. okt. 2025210 deltagereSponsor: Novo Nordisk A/SNCT05726227

  2. Fase 3Aktivt, rekrutterer ikke

    Afamelanotide plus NB-UVB in vitiligo(åbner kilden i en ny fane)

    A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo

    Primær afslutning forventet december 2025200 deltagereSponsor: Clinuvel, Inc.NCT06109649

  3. Fase 2, Fase 3Aktivt, rekrutterer ikke

    Intranasal oxytocin for chronic pain(åbner kilden i en ny fane)

    Evaluating the Efficacy of Intranasal Oxytocin on Chronic Pain

    Primær afslutning forventet 31. mar. 2026336 deltagereSponsor: Memorial University of NewfoundlandNCT04903002

  4. Fase 2Rekrutterer

    Mazdutide in MASH(åbner kilden i en ny fane)

    A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

    Primær afslutning forventet 30. apr. 2026165 deltagereSponsor: Innovent Biologics (Suzhou) Co. Ltd.NCT06937749

  5. Fase 2Rekrutterer

    Vosoritide in idiopathic short stature(åbner kilden i en ny fane)

    A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

    Primær afslutning forventet juni 2026100 deltagereSponsor: BioMarin PharmaceuticalNCT06382155

  6. Fase 3Aktivt, rekrutterer ikke

    SURMOUNT-ADOLESCENTS(åbner kilden i en ny fane)

    A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

    Primær afslutning 2. jun. 2026160 deltagereSponsor: Eli Lilly and CompanyNCT06075667

  7. Fase 3Aktivt, rekrutterer ikke

    CANOPY-HCH-3(åbner kilden i en ny fane)

    Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia

    Primær afslutning forventet 1. aug. 202680 deltagereSponsor: BioMarin PharmaceuticalNCT06455059

  8. Fase 3Rekrutterer

    Mazdutide in hypertension(åbner kilden i en ny fane)

    Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity

    Primær afslutning forventet 1. aug. 2026336 deltagereSponsor: Innovent Biologics (Suzhou) Co. Ltd.NCT07469800

  9. Fase 3Aktivt, rekrutterer ikke

    TRANSCEND-T2D-2(åbner kilden i en ny fane)

    Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

    Primær afslutning 27. aug. 20261.250 deltagereSponsor: Eli Lilly and CompanyNCT06260722

  10. Fase 2Aktivt, rekrutterer ikke

    INFLAM MOTION(åbner kilden i en ny fane)

    A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis

    Primær afslutning 31. aug. 2026129 deltagereSponsor: 4Moving BiotechNCT07225829

  11. Fase 2Aktivt, rekrutterer ikke

    Mazdutide in heart failure(åbner kilden i en ny fane)

    A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity

    Primær afslutning forventet 24. sep. 2026141 deltagereSponsor: Innovent Biologics (Suzhou) Co. Ltd.NCT06862908

  12. Fase 2Aktivt, rekrutterer ikke

    Linaclotide in colorectal neoplasia(åbner kilden i en ny fane)

    Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer

    Primær afslutning forventet 30. sep. 2026150 deltagereSponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityNCT03796884

  13. Fase 2Rekrutterer

    OxyTUTION(åbner kilden i en ny fane)

    Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus

    Primær afslutning forventet oktober 2026112 deltagereSponsor: University Hospital, Basel, SwitzerlandNCT06036004

  14. Fase 2Rekrutterer endnu ikke

    Sublingual oxytocin for PPH(åbner kilden i en ny fane)

    Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage

    Primær afslutning forventet 30. okt. 2026330 deltagereSponsor: Insud PharmaNCT06968481

  15. Fase 3Aktivt, rekrutterer ikke

    SURPASS-T1D-1(åbner kilden i en ny fane)

    A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

    Primær afslutning forventet november 2026905 deltagereSponsor: Eli Lilly and CompanyNCT06914895

  16. Fase 3Aktivt, rekrutterer ikke

    TRIUMPH-5(åbner kilden i en ny fane)

    A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

    Primær afslutning forventet november 2026800 deltagereSponsor: Eli Lilly and CompanyNCT06662383

  17. Fase 3Aktivt, rekrutterer ikke

    OVELIA(åbner kilden i en ny fane)

    Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

    Primær afslutning forventet 30. nov. 2026250 deltagereSponsor: Tolmar Inc.NCT04906395

  18. Fase 2Aktivt, rekrutterer ikke

    LOCITT(åbner kilden i en ny fane)

    The Long COVID Treatment Trial

    Primær afslutning forventet december 20261.000 deltagereSponsor: Scripps Translational Science InstituteNCT07128082

  19. Fase 3Aktivt, rekrutterer ikke

    GLORY-3(åbner kilden i en ny fane)

    A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）

    Primær afslutning forventet 31. dec. 2026479 deltagereSponsor: Innovent Biologics (Suzhou) Co. Ltd.NCT06884293

  20. Fase 2Aktivt, rekrutterer ikke

    FAST-Healing(åbner kilden i en ny fane)

    Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery

    Primær afslutning forventet februar 202796 deltagereSponsor: Hospital for Special Surgery, New YorkNCT03841058

  21. Fase 2, Fase 3Rekrutterer

    Thy-α1 for RIF(åbner kilden i en ny fane)

    Thymosin-α1 for Recurrent Implantation Failure

    Primær afslutning forventet februar 2027136 deltagereSponsor: Fakih IVF Fertility CenterNCT07675980

  22. Fase 3Aktivt, rekrutterer ikke

    Teduglutide in Chinese adults with SBS(åbner kilden i en ny fane)

    A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome

    Primær afslutning forventet 10. feb. 202713 deltagereSponsor: TakedaNCT06973304

  23. Fase 2Rekrutterer

    INHALE-1st(åbner kilden i en ny fane)

    INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes

    Primær afslutning forventet marts 2027100 deltagereSponsor: Mannkind CorporationNCT07224321

  24. Fase 3Rekrutterer

    Congenital hypothalamic obesity(åbner kilden i en ny fane)

    A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

    Primær afslutning forventet 13. mar. 202739 deltagereSponsor: Rhythm Pharmaceuticals, Inc.NCT06760546

  25. Fase 3Rekrutterer

    Liraglutide for delirium after surgery(åbner kilden i en ny fane)

    Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery

    Primær afslutning forventet 31. mar. 2027260 deltagereSponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT06361238

  26. Fase 3Rekrutterer

    Thymosin alpha-1 in colorectal cancer(åbner kilden i en ny fane)

    Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

    Primær afslutning forventet 31. mar. 20272.500 deltagereSponsor: Fudan UniversityNCT05086614

  27. Fase 3Rekrutterer endnu ikke

    Oral insulin ORMD-0801 in T2D(åbner kilden i en ny fane)

    A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.

    Primær afslutning forventet 25. apr. 2027300 deltagereSponsor: Oramed, Ltd.NCT06731075

  28. Fase 3Rekrutterer endnu ikke

    Abaloparatide vs teriparatide in China(åbner kilden i en ny fane)

    To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture

    Primær afslutning forventet maj 2027282 deltagereSponsor: Qilu Pharmaceutical Co., Ltd.NCT06898060

  29. Fase 3Rekrutterer

    GLORY-OSA(åbner kilden i en ny fane)

    A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2

    Primær afslutning forventet 7. maj 2027260 deltagereSponsor: Innovent Biologics (Suzhou) Co. Ltd.NCT06931028

  30. Fase 3Aktivt, rekrutterer ikke

    RENEW 1(åbner kilden i en ny fane)

    Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

    Primær afslutning forventet 11. maj 2027300 deltagereSponsor: Novo Nordisk A/SNCT07220642

  31. Fase 3Aktivt, rekrutterer ikke

    RENEW 2(åbner kilden i en ny fane)

    Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

    Primær afslutning forventet 12. maj 2027330 deltagereSponsor: Novo Nordisk A/SNCT07220759

  32. Fase 3Aktivt, rekrutterer ikke

    ReNEW(åbner kilden i en ny fane)

    ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

    Primær afslutning forventet august 2027313 deltagereSponsor: Stealth BioTherapeutics Inc.NCT06373731

  33. Fase 3Aktivt, rekrutterer ikke

    Adjuvant leuprorelin after prostatectomy(åbner kilden i en ny fane)

    Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.

    Primær afslutning forventet september 2027700 deltagereSponsor: UNICANCERNCT01442246

  34. Fase 3Rekrutterer

    OPIC(åbner kilden i en ny fane)

    Oxytocin vs Prostaglandins for Labor Induction of Women With an Unfavorable Cervix After 24h of Cervical Ripening

    Primær afslutning forventet september 20271.494 deltagereSponsor: University Hospital, ToursNCT04949633

  35. Fase 3Aktivt, rekrutterer ikke

    TRIUMPH-7(åbner kilden i en ny fane)

    A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

    Primær afslutning forventet september 2027586 deltagereSponsor: Eli Lilly and CompanyNCT07035093

  36. Fase 3Aktivt, rekrutterer ikke

    REDEFINE 3(åbner kilden i en ny fane)

    REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

    Primær afslutning forventet 1. sep. 20277.101 deltagereSponsor: Novo Nordisk A/SNCT05669755

  37. Fase 2Rekrutterer

    TAB(åbner kilden i en ny fane)

    Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

    Primær afslutning forventet 30. sep. 2027310 deltagereSponsor: T. John Winhusen, PhDNCT06651177

  38. Fase 3Aktivt, rekrutterer ikke

    SURMOUNT-MMO(åbner kilden i en ny fane)

    A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

    Primær afslutning forventet oktober 202715.374 deltagereSponsor: Eli Lilly and CompanyNCT05556512

  39. Fase 3Aktivt, rekrutterer ikke

    ADOPT(åbner kilden i en ny fane)

    Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy

    Primær afslutning forventet 21. okt. 2027280 deltagereSponsor: University Medical Center GroningenNCT04302454

  40. Fase 3Rekrutterer

    GLORY-YOUNG(åbner kilden i en ny fane)

    A Study of IBI362 in Chinese Adolescents With Obesity or Overweight

    Primær afslutning forventet 31. okt. 2027180 deltagereSponsor: Innovent Biologics (Suzhou) Co. Ltd.NCT07255209

  41. Fase 3Aktivt, rekrutterer ikke

    FOCUS(åbner kilden i en ny fane)

    A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

    Primær afslutning forventet 7. nov. 20271.500 deltagereSponsor: Novo Nordisk A/SNCT03811561

  42. Fase 2Rekrutterer endnu ikke

    ARTIST-CKD(åbner kilden i en ny fane)

    Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease

    Primær afslutning forventet 30. nov. 2027120 deltagereSponsor: University Medical Center GroningenNCT07206290

  43. Fase 3Rekrutterer

    AWARD-PEDS PLUS(åbner kilden i en ny fane)

    A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

    Primær afslutning forventet december 202755 deltagereSponsor: Eli Lilly and CompanyNCT06739122

  44. Fase 3Rekrutterer

    Survodutide in type 2 diabetes(åbner kilden i en ny fane)

    A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Primær afslutning forventet 17. jan. 2028600 deltagereSponsor: Boehringer IngelheimNCT07754461

  45. Fase 2Rekrutterer

    TRIUMPH (tesamorelin)(åbner kilden i en ny fane)

    Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

    Primær afslutning forventet 16. jun. 2028100 deltagereSponsor: Massachusetts General HospitalNCT06554717

  46. Fase 3Rekrutterer

    AMAZE 9(åbner kilden i en ny fane)

    AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

    Primær afslutning forventet 27. jun. 2028950 deltagereSponsor: Novo Nordisk A/SNCT07720271

  47. Fase 2Rekrutterer

    Vosoritide in infant hypochondroplasia(åbner kilden i en ny fane)

    A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months

    Primær afslutning forventet 30. jun. 202860 deltagereSponsor: BioMarin PharmaceuticalNCT07126262

  48. Fase 3Rekrutterer

    AMAZE 3(åbner kilden i en ny fane)

    AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

    Primær afslutning forventet 12. jul. 2028300 deltagereSponsor: Novo Nordisk A/SNCT07571005

  49. Fase 3Rekrutterer endnu ikke

    SYNCHRONIZE-HERA(åbner kilden i en ny fane)

    SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight

    Primær afslutning forventet 26. jul. 2028600 deltagereSponsor: Boehringer IngelheimNCT07850050

  50. Fase 3Rekrutterer

    AMBITION 7(åbner kilden i en ny fane)

    AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

    Primær afslutning forventet 31. jul. 20281.778 deltagereSponsor: Novo Nordisk A/SNCT07797335

  51. Fase 3Rekrutterer

    AMAZE 2(åbner kilden i en ny fane)

    AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

    Primær afslutning forventet 7. aug. 2028630 deltagereSponsor: Novo Nordisk A/SNCT07533175

  52. Fase 3Rekrutterer

    AMAZE 5(åbner kilden i en ny fane)

    A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

    Primær afslutning forventet 14. aug. 2028400 deltagereSponsor: Novo Nordisk A/SNCT07481630

  53. Fase 2Rekrutterer

    CBCT-OT RCT(åbner kilden i en ny fane)

    Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD

    Primær afslutning forventet 30. sep. 2028240 deltagereSponsor: VA Office of Research and DevelopmentNCT06194851

  54. Fase 3Rekrutterer

    AMAZE 7(åbner kilden i en ny fane)

    A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

    Primær afslutning forventet 10. okt. 2028650 deltagereSponsor: Novo Nordisk A/SNCT07668414

  55. Fase 2, Fase 3Rekrutterer

    Pulsatile GnRH in Down syndrome(åbner kilden i en ny fane)

    GnRH Therapy on Cognition in Down Syndrome

    Primær afslutning forventet december 202856 deltagereSponsor: Nelly PitteloudNCT04390646

  56. Fase 3Rekrutterer endnu ikke

    AMAZE 8(åbner kilden i en ny fane)

    AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

    Primær afslutning forventet 12. dec. 20281.000 deltagereSponsor: Novo Nordisk A/SNCT07400107

Afsluttet eller stoppet

  1. Fase 2Afsluttet

    Thymosin alpha-1 in lung cancer(åbner kilden i en ny fane)

    The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

    Primær afslutning 30. jun. 2026114 deltagereSponsor: Sun Yat-sen UniversityNCT06139419

  2. Fase 3Afsluttet

    TRIUMPH-2(åbner kilden i en ny fane)

    A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

    Primær afslutning 16. jun. 20261.152 deltagereSponsor: Eli Lilly and CompanyNCT05929079

  3. Fase 3Afsluttet

    SYNCHRONIZE-CVOT(åbner kilden i en ny fane)

    A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

    Primær afslutning 1. jun. 20265.531 deltagereSponsor: Boehringer IngelheimNCT06077864

  4. Fase 3Afsluttet

    TRIUMPH-3(åbner kilden i en ny fane)

    A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

    Primær afslutning 16. apr. 20261.946 deltagereSponsor: Eli Lilly and CompanyNCT05882045

  5. Fase 2Afsluttet

    COPE+OT(åbner kilden i en ny fane)

    Oxytocin to Enhance Integrated Treatment for AUD and PTSD

    Primær afslutning 13. apr. 2026175 deltagereSponsor: Medical University of South CarolinaNCT04523922

  6. Fase 3Afsluttet

    TRIUMPH-1(åbner kilden i en ny fane)

    A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

    Primær afslutning 6. apr. 20262.335 deltagereSponsor: Eli Lilly and CompanyNCT05929066

  7. Fase 2Afsluttet

    Mazdutide in alcohol use disorder(åbner kilden i en ny fane)

    A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder

    Primær afslutning 19. mar. 2026308 deltagereSponsor: Eli Lilly and CompanyNCT06817356

  8. Fase 3Afsluttet

    TRANSCEND-T2D-1(åbner kilden i en ny fane)

    Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

    Primær afslutning 22. jan. 2026537 deltagereSponsor: Eli Lilly and CompanyNCT06354660

  9. Fase 3Afsluttet

    TOGETHER-PsO(åbner kilden i en ny fane)

    Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

    Primær afslutning 8. jan. 2026281 deltagereSponsor: Eli Lilly and CompanyNCT06588283

  10. Fase 3Afsluttet

    EMANATE(åbner kilden i en ny fane)

    EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway

    Primær afslutning 22. dec. 2025296 deltagereSponsor: Rhythm Pharmaceuticals, Inc.NCT05093634

  11. Fase 3Afsluttet

    SYNCHRONIZE-2(åbner kilden i en ny fane)

    A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

    Primær afslutning 12. dec. 2025755 deltagereSponsor: Boehringer IngelheimNCT06066528

  12. Fase 3Afsluttet

    CagriSema vs tirzepatide in obesity(åbner kilden i en ny fane)

    A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

    Primær afslutning 8. dec. 2025809 deltagereSponsor: Novo Nordisk A/SNCT06131437

  13. Fase 3Afsluttet

    Leuprolide mesylate in early puberty(åbner kilden i en ny fane)

    Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty

    Primær afslutning 7. dec. 202594 deltagereSponsor: Foresee Pharmaceuticals Co., Ltd.NCT05493709

  14. Fase 3Afsluttet

    SYNCHRONIZE-1(åbner kilden i en ny fane)

    A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

    Primær afslutning 2. dec. 2025726 deltagereSponsor: Boehringer IngelheimNCT06066515

  15. Fase 3Afsluttet

    REIMAGINE 2(åbner kilden i en ny fane)

    A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

    Primær afslutning 19. nov. 20252.734 deltagereSponsor: Novo Nordisk A/SNCT06065540

  16. Fase 3Afsluttet

    TRIUMPH-4(åbner kilden i en ny fane)

    A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

    Primær afslutning 14. nov. 2025445 deltagereSponsor: Eli Lilly and CompanyNCT05931367

  17. Fase 2Afsluttet

    Exenatide for smoking cessation(åbner kilden i en ny fane)

    Exenatide for Smoking Cessation and Prevention of Weight Gain

    Primær afslutning 7. nov. 2025140 deltagereSponsor: The University of Texas Health Science Center, HoustonNCT05610800

  18. Fase 3Afsluttet

    SYNCHRONIZE-MASLD(åbner kilden i en ny fane)

    A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)

    Primær afslutning 9. okt. 2025218 deltagereSponsor: Boehringer IngelheimNCT06309992

  19. Fase 2Afsluttet

    Amycretin in type 2 diabetes(åbner kilden i en ny fane)

    A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

    Primær afslutning 1. okt. 2025448 deltagereSponsor: Novo Nordisk A/SNCT06542874

  20. Fase 3Afsluttet

    DREAMS-3(åbner kilden i en ny fane)

    A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity

    Primær afslutning 17. sep. 2025349 deltagereSponsor: Innovent Biologics (Suzhou) Co. Ltd.NCT06184568

  21. Fase 3Afsluttet

    EVOKE(åbner kilden i en ny fane)

    A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

    Primær afslutning 16. sep. 20251.840 deltagereSponsor: Novo Nordisk A/SNCT04777396

  22. Fase 3Afsluttet

    EVOKE Plus(åbner kilden i en ny fane)

    A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

    Primær afslutning 15. sep. 20251.840 deltagereSponsor: Novo Nordisk A/SNCT04777409

  23. Fase 3AfsluttetResultater offentliggjort

    Linaclotide in constipation, ages 2 to 5(åbner kilden i en ny fane)

    A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

    Primær afslutning 2. sep. 2025123 deltagereSponsor: AbbVieNCT05652205

  24. Fase 2Afsluttet

    SEMALCO(åbner kilden i en ny fane)

    Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

    Primær afslutning 31. jul. 2025108 deltagereSponsor: Psychiatric Centre RigshospitaletNCT05895643